Cargando…
Chromatin deregulation in disease
The regulation of chromatin by epigenetic mechanisms plays a central role in gene expression and is essential for development and maintenance of cell identity and function. Aberrant chromatin regulation is observed in many diseases where it leads to defects in epigenetic gene regulation resulting in...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761009/ https://www.ncbi.nlm.nih.gov/pubmed/26188466 http://dx.doi.org/10.1007/s00412-015-0530-0 |
_version_ | 1782416925072031744 |
---|---|
author | Mirabella, Anne C. Foster, Benjamin M. Bartke, Till |
author_facet | Mirabella, Anne C. Foster, Benjamin M. Bartke, Till |
author_sort | Mirabella, Anne C. |
collection | PubMed |
description | The regulation of chromatin by epigenetic mechanisms plays a central role in gene expression and is essential for development and maintenance of cell identity and function. Aberrant chromatin regulation is observed in many diseases where it leads to defects in epigenetic gene regulation resulting in pathological gene expression programmes. These defects are caused by inherited or acquired mutations in genes encoding enzymes that deposit or remove DNA and histone modifications and that shape chromatin architecture. Chromatin deregulation often results in neurodevelopmental disorders and intellectual disabilities, frequently linked to physical and developmental abnormalities, but can also cause neurodegenerative diseases, immunodeficiency, or muscle wasting syndromes. Epigenetic diseases can either be of monogenic origin or manifest themselves as complex multifactorial diseases such as in congenital heart disease, autism spectrum disorders, or cancer in which mutations in chromatin regulators are contributing factors. The environment directly influences the epigenome and can induce changes that cause or predispose to diseases through risk factors such as stress, malnutrition or exposure to harmful chemicals. The plasticity of chromatin regulation makes targeting the enzymatic machinery an attractive strategy for therapeutic intervention and an increasing number of small molecule inhibitors against a variety of epigenetic regulators are in clinical use or under development. In this review, we will give an overview of the molecular lesions that underlie epigenetic diseases, and we will discuss the impact of the environment and prospects for epigenetic therapies. |
format | Online Article Text |
id | pubmed-4761009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-47610092016-03-01 Chromatin deregulation in disease Mirabella, Anne C. Foster, Benjamin M. Bartke, Till Chromosoma Review The regulation of chromatin by epigenetic mechanisms plays a central role in gene expression and is essential for development and maintenance of cell identity and function. Aberrant chromatin regulation is observed in many diseases where it leads to defects in epigenetic gene regulation resulting in pathological gene expression programmes. These defects are caused by inherited or acquired mutations in genes encoding enzymes that deposit or remove DNA and histone modifications and that shape chromatin architecture. Chromatin deregulation often results in neurodevelopmental disorders and intellectual disabilities, frequently linked to physical and developmental abnormalities, but can also cause neurodegenerative diseases, immunodeficiency, or muscle wasting syndromes. Epigenetic diseases can either be of monogenic origin or manifest themselves as complex multifactorial diseases such as in congenital heart disease, autism spectrum disorders, or cancer in which mutations in chromatin regulators are contributing factors. The environment directly influences the epigenome and can induce changes that cause or predispose to diseases through risk factors such as stress, malnutrition or exposure to harmful chemicals. The plasticity of chromatin regulation makes targeting the enzymatic machinery an attractive strategy for therapeutic intervention and an increasing number of small molecule inhibitors against a variety of epigenetic regulators are in clinical use or under development. In this review, we will give an overview of the molecular lesions that underlie epigenetic diseases, and we will discuss the impact of the environment and prospects for epigenetic therapies. Springer Berlin Heidelberg 2015-07-19 2016 /pmc/articles/PMC4761009/ /pubmed/26188466 http://dx.doi.org/10.1007/s00412-015-0530-0 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Mirabella, Anne C. Foster, Benjamin M. Bartke, Till Chromatin deregulation in disease |
title | Chromatin deregulation in disease |
title_full | Chromatin deregulation in disease |
title_fullStr | Chromatin deregulation in disease |
title_full_unstemmed | Chromatin deregulation in disease |
title_short | Chromatin deregulation in disease |
title_sort | chromatin deregulation in disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761009/ https://www.ncbi.nlm.nih.gov/pubmed/26188466 http://dx.doi.org/10.1007/s00412-015-0530-0 |
work_keys_str_mv | AT mirabellaannec chromatinderegulationindisease AT fosterbenjaminm chromatinderegulationindisease AT bartketill chromatinderegulationindisease |